Cyclosporin A in asthma therapy: a pharmacological rationale.
Lymphocytes play a central role in immunological reactions and control the mobilisation and recruitment into lung tissue of eosinophils and mast cells. Since cyclosporin A can profoundly influence lymphocyte activation, it is appropriate to consider this drug as a novel anti-asthma therapy. Inhalation of low doses of cyclosporin A strongly inhibits the influx of inflammatory cells into the airways during acute allergic reactions, even though associated bronchospasm and airway hyper-reactivity are undiminished. It is suggested that cyclosporin A will be an effective anti-asthma therapy with an anti-asthma profile resembling that of established glucocorticosteroids.
Morley
J
J
Preclinical Research, Sandoz Pharma Ltd, Basel, Switzerland.
D000818:Animals; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology; D016572:Cyclosporine / Q000627:therapeutic use*; D004802:Eosinophilia / Q000188:drug therapy; D004804:Eosinophils / Q000276:immunology; D006168:Guinea Pigs; D006801:Humans; D007111:Immunity, Cellular; D008214:Lymphocytes / Q000276:immunology; D051381:Rats
D016572:Cyclosporine